(Q51365356)

4 April 2018

title

Efficacy and safety of saxagliptin in drug-naïve Asian patients with type 2 diabetes mellitus: a randomized controlled trial. (English)

1 reference

4 April 2018

0 references

0 references

1 reference

ChEBI release 2020-05-28

Chang Yu Pan

1

1 reference

4 April 2018

Wenying Yang

2

1 reference

4 April 2018

Conrad Tou

3

1 reference

4 April 2018

Ingrid Gause-Nilsson

4

1 reference

4 April 2018

June Zhao

5

1 reference

4 April 2018

publication date

1 March 2012

1 reference

4 April 2018

Diabetes - Metabolism: Research and Reviews

published in

1 reference

4 April 2018

volume

28

1 reference

4 April 2018

issue

3

1 reference

4 April 2018

page(s)

268-275

1 reference

4 April 2018

Type 2 diabetes in China: partnerships in education and research to evaluate new antidiabetic treatments

cites work

1 reference

Obesity and diabetes in the developing world--a growing challenge

21 January 2018

1 reference

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study

21 January 2018

1 reference

Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus

21 January 2018

1 reference

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

21 January 2018

1 reference

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

21 January 2018

1 reference

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

21 January 2018

1 reference

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

Use and abuse of HOMA modeling

21 January 2018

1 reference

The status of diabetes control in Asia--a cross-sectional survey of 24 317 patients with diabetes mellitus in 1998.

21 January 2018

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

Diabetes in Asia: epidemiology, risk factors, and pathophysiology

21 January 2018

1 reference

Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control

21 January 2018

1 reference

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/DMRR.1306

1 reference

4 April 2018

1 reference

4 April 2018